CB2 exerts pro-tumor effects by suppressing cytotoxicity of CD8+ T cells and NK cells. Simultaneous antagonism of CB2 enhances anti-tumor effects of anti-PD-1 therapy. The gene discussed is CD8A; the disease is neoplasm.